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1. Introduction 
Recent advances in biotechnology gave rise to a set of microarray technologies that became 
ubiquitous in research, medicine, and industry for tens of applications. Microarray 
technology has centered on providing platforms for analyzing, in a single experiment, tens 
or even hundreds of samples from different biologic sources. Its rapid and global adoption 
has been predicated on its simplicity and efficiency in quickly providing relevant data 
generated by simultaneous testing of biological samples with a large number of probes. In 
this chapter, we describe new microarray approaches that have considerably simplified the 
characterization of viral genes and genomes with specific emphasis on analysis of the 
genetic stability of live viral vaccines.  
There are different types of vaccines that immunize against viruses: whole viral vaccines 
(either live attenuated or inactivated), subunit vaccines; purified or recombinant viral 
antigen vaccines, and DNA vaccines.  
Genetic instability and plasticity of genomes are inherent properties of viruses, especially 
RNA viruses, with many profound implications for their replication, evolution, and 
pathogenesis. Because of the presence of a large number of mutants, populations of viruses 
are often described as quasispecies (Domingo et al., 1985; Hansen et al., 2004). Most mutants 
are present at a relatively low level, making them difficult to detect using conventional 
sequencing methods.  
Genetic stability of live viral vaccines, including recombinant virus vaccines, is a key 
element of their safety and protective efficacy. Assessment of genetic stability is an 
important part of pre-licensure evaluation and quality control of a live viral vaccine, both 
during its manufacturing and after its administration.  Spontaneous mutations easily 
emerge during viral replication and accumulation of mutants must be identified to ensure 
the safety of live vaccines.  
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To ensure maximum genetic stability and to optimize genetic structure of prospective live 
vaccine strains, it is important to identify the mutations that accumulate both during 
manufacturing and replication in vaccine recipients. Incorporation of mutations that 
increase virus fitness and do not affect its attenuation into the genetic makeup of the new 
vaccine strain may increase its potency and contribute to genetic stability 
Most new viral vaccines are produced by propagation in cell cultures that do not necessarily 
represent the natural substrate for the virus, raising the possibility of introducing 
undesirable mutations in the course of virus adaptation. RNA viral vaccines mutate easily 
upon passage in cell cultures, which can change the phenotype (Amexis et al., 2001), leading 
to increased pathogenicity. That occurred with pSPBNGA-GA, a live rabies virus 
recombinant vaccine candidate, which was obtained via reverse genetics (Dietzschold et al., 
2004). Additionally, it was demonstrated that some deletions in HIV-1 vaccine strains can 
evolve into fast-replicating variants by multiplication of remaining sequence motifs, and 
their safety is therefore not guaranteed (Berkhout et al., 1999), and the presence of even a 
small fraction of viral mutants in an oral poliovirus vaccine can have negative effect on its 
safety (Chumakov et al., 1991), suggesting that genetic consistency must be carefully 
monitored to ensure that accumulated mutants do not adversely impair the safety and 
efficacy of the vaccine. 
In addition, vaccines have been recently developed to serve as live viral vectors expressing 
heterologous host genes. Examples of such live viral vectors include herpesviruses (such as 
pseudorabies and bovine herpesvirus type 1, and 2), poxviruses (Blancou et al., 1986; 
Fekadu et al., 1991; Taylor et al., 1991), human adenovirus 5, (Prevec et al., 1990) and 
flaviviruses (Arroyo et al., 2001; Monath et al., 1999; Pletnev et al., 2001; Pletnev et al., 1992; 
Pletnev et al., 2000; Pletnev and Men, 1998; Pletnev et al., 2002; Pletnev et al., 2006). The 
recombination in genomes of chimeric viruses probably plays an important role in the 
reduction of viral fitness that leads to attenuation. This creates a selective pressure to 
accumulate mutants that restore viral fitness by adapting heterologous genomic parts to 
each other, potentially leading to a loss of attenuation. The accumulation of mutations and 
genetic stability of flaviviruses were previously reported (Dunster et al., 1999; Laassri et al., 
2011; Pugachev et al., 2004; Pugachev et al., 2002; Pugachev et al., 2007). 
Of paramount importance is the need to demonstrate the genetic stability of the 
recombinant construct and confirm the fidelity of the heterologous gene inserted into the 
vector genome (WHO, 1990). An important consideration for the licensure and use of any 
genetically engineered live vaccine is the stability of the vector and that of the recombinant 
construct. In addition, genetic stability is an important safety concern, since predictions of 
vaccine behavior rely heavily on the knowledge of the genetic makeup of the recombinant. 
If a recombinant vaccine is to be useful, it should undergo no substantial mutation either 
during production of the vaccine by passage of working seed or after administration to the 
target species. 
Therefore, it is essential to identify genomic loci that are prone to mutations and determine 
their phenotypes. If mutations in unstable genomic loci increase virulence, then methods to 
prevent their emergence and control their presence in vaccine preparations must be 
developed. On the other hand, if the fitness-restoring mutants do not lead to de-attenuation, 
then it may be desirable to incorporate them into the genetic makeup of the vaccine strain. 
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Additionally, increased yields of such viruses during vaccine production may help stabilize 
the genome by relieving selective pressure, thereby preventing random and potentially 
undesirable mutations from being passively selected through the “passenger effect”.  
Conventional assays of genetic stability of viruses by combined sequencing and sequence 
analysis are generally too insensitive to detect small proportion of mutant viruses in a 
quasispecies, and are laborious. Thus, sensitive high-throughput microarray techniques 
including microarray for resequencing and sequence heterogeneity (MARSH), microarray 
analysis of viral recombination (MAVR) assay, and microarray for quantitation of known 
virulent mutations (MQNVM) have been developed and applied as valuable tools to 
evaluate the genetic stability of live viral vaccines (Cherkasova et al., 2003; Laassri et al., 
2011; Laassri et al., 2005; Laassri et al., 2007). 
These microarray approaches allow large-scale full-genome mutational screening of live 
viral vaccines from various sources including cell culture, humans, monkeys, and mice. 
They can be used to improve quality control and to accelerate development of safer and 
more effective vaccines. The study of genetic stability also contributes to our understanding 
of live viral vaccine evolution. 
2. DNA microarray: An overview 
DNA microarray is a high-throughput hybridization technology used for quantitative and 
qualitative assessments of gene-expression, chromosomal aberrations, and mutations in 
molecular biology and biotechnology. It consists of an arrayed series of tens or thousands of 
micro-spots of oligonucleotides of specific DNA sequence, known as probes. Probes can be 
short regions of a gene or other DNA elements used to hybridize DNA or RNA samples 
(targets) under high-stringency conditions. Probe-target hybridizations are usually detected 
and quantified using fluorophore-labeled targets to determine the relative quantities of 
nucleic acid sequences in the target. Since an array can contain tens of thousands of probes, 
a microarray experiment enables analysis of many genes simultaneously. Therefore, arrays 
have dramatically accelerated many types of investigations.  
In standard microarrays, the probes are attached via their engineered chemical group to a 
solid surface by a covalent bond to a chemical matrix (via epoxy - silane, amino-silane, 
lysine, polyacrylamide, or others). The solid surface can be glass, a silicon chip, or 
microscopic beads.  
DNA microarrays can be used to measure changes in expression level, to detect and 
quantify single nucleotide polymorphisms (SNPs), to genotype and resequence mutant 
genomes, or to determine recombinant nucleotide sequences. Microarrays vary in 
fabrication, operating protocols, accuracy, and efficiency. Additional factors affecting 
microarray experiments are experimental design and methods for analyzing the data. 
3. Microarray for resequencing and sequence heterogeneity 
Several approaches based on hybridization of viral probes with oligonucleotide microarrays 
have been applied for rapid analysis of genetic variations during the microevolution of 
viruses. Microarray for resequencing and sequence heterogeneity (MARSH) was used to 
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identify mutations in vaccine viruses and their derivatives, revealing the degree of their 
evolutionary divergence and quantifying mutant genome proportions present.  
The MARSH assay was based on the hybridization of fluorescently-labeled RNA produced 
from the virus genome with microarrays of oligonucleotide probes that are complementary 
to and cover the entire viral genome or specific genes. Quantitative comparison of 
hybridization data produced for a test sample with the data for homogeneous reference 
RNA reveal mutations that have emerged and accumulated during the replication of vaccine 
strains in vitro or in vivo (Figure 1). 
MARSH (Figure 1) microchips were fabricated using a set of short oligonucleotides (Tm ~ 
50°C) overlapping at half length, matching genomic sequences of virus strains, and covering 
a specific viral region of interest in the genome or the entire viral genome. Each 
oligonucleotide probe was synthesized with an aminolink group at its 5’ end for 
immobilization on a specific platform and purified after automated synthesis. Microarrays 
were printed on sialylated (aldehyde-coated) glass slides by using a contact microspotting 
robot equipped with a microspotting pin. Each oligonucleotide probe was spotted several 
times within a single microarray for redundancy to increase the reliability of results. 
For RNA viruses, cDNA was prepared with reverse transcriptase using a specific reverse 
primer at the 3’ end region of the genome. Microarrays of immobilized oligonucleotide 
probes were hybridized with fluorescently-labeled RNA transcribed by T7 RNA polymerase 
from PCR-amplified viral cDNA. First, the viral genome was amplified using the specific 
primers (the reverse primer contains T7 promotor) to produce the needed DNA segments. 
RNA for hybridization was produced by in vitro transcription of the PCR products with a T7 
RNA polymerase kit. Each RNA product (~10 µg) can be fluorescently labeled with a Cy3 
RNA Labeling Kit. Labeled RNA samples were purified using spin columns.  
Microarray hybridization was performed as follow: fluorescently-labeled RNA samples 
were vacuum-dried prior to hybridization, reconstituted in Hybridization Buffer, and 
denatured by incubation for one minute at 95°C. The final concentration of each fluorescent 
target in the hybridization solution should not exceed 0.1 M. An aliquot of the 
hybridization mixture (~10 l) was applied to the microarray area and covered with an 
individual plastic cover slip. Hybridization was performed in an incubation chamber for one 
hour at 45°C. Fluorescent images of processed microarray slides were captured using a 
ScanArray 5000, and the images were analyzed using ScanArray Express software. 
In the experiments presented on Figure 1, each microarray contained 4 identical sub-arrays 
that were simultaneously hybridized in order to assess reproducibility of the hybridization 
results and to eliminate outlier data points. Hybridization signals from individual sub-array 
elements that differ from the average value were calculated for all 4 replicates of the 
oligonucleotide probes by more than two standard deviations were discarded; the number 
of such invalidated data points should not exceed 0.1%. Next, average values from the 4 
sub-arrays were normalized by the total fluorescence signal from the entire array. Finally, 
normalized signals from the reference sample (homogeneous RNA) were divided by the 
respective normalized signals from the test samples, and the results were expressed as a 
fluorescence ratio (Figure 1C). Regions with no mutations should have ratios close to one, 
while test samples with mutations reduced hybridization with some oligonucleotide probes 
and therefore, produce ratios greater than one.  
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The MARSH assay was first used to analyze mutations that accumulate in the region coding 
for VP1, the most variable capsid protein of poliovirus (Cherkasova et al., 2003; Laassri et al., 
2005). Later, this microarray approach was expanded to discriminate between vaccinia 
strains and to evaluate genetic stability of the vaccinia virus Ankara (MVA) B5R gene 
following propagation of a cloned isolate of MVA in Vero and MRC-5 cell lines (Laassri et 
al., 2007), to analyze the variability of the structural region of West Nile (WN) virus (Grinev 
et al., 2008), and to evaluate stability of the entire genome of a WN/Dengue 4 chimeric virus 
under study as a new candidate of WN vaccine (Laassri et al., 2011).  
The MARSH microarray approach facilitates rapid analysis of viral genes and genomes, and 
circumvents traditional more laborious methods. With the microarray method, many 
samples can be analyzed simultaneously within a few hours. Furthermore, test samples do 
not need to be cloned, thus preserving the natural composition of viral gene populations. 
This method permits large-scale full genome screening of viral isolates, useful for 
epidemiological surveillance, vaccine quality control, and analysis of genetic changes in 
viruses that may occur in response to drug treatment.  
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Fig. 1. Schematic overview of the MARSH assay: (A) Oligonucleotide microarray containing 
short oligonucleotides overlapped at half-length covering the entire viral genome. Each 
microarray has four identical sub-arrays hybridized at the same time. (B) Images of 4 
individual identical sub-arrays hybridized with control sample. (C) Ratio of hybridization 
signals from reference and test sample preparations was plotted to reveal peaks indicating 
the presence of mutations. The hybridization images and the ratio plot are cartoons given 
for illustration purposes only. 
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4. Microarray analysis of viral recombination assay 
Microarray analysis of viral recombination (MAVR) assay is, in essence, an extension of the 
genotype-specific oligonucleotide microarrays previously used to identify different viruses 
and bacteria (Laassri et al., 2003; Volokhov et al., 2003). The MAVR assay was developed to 
detect recombinations between the three serotypes of oral poliovirus vaccine (OPV) 
(Cherkasova et al., 2003; Laassri et al., 2005). The locations of oligonucleotide spots within 
the poliovirus MAVR microarray produce an image that graphically reveals genomic 
recombination patterns and crossover regions (Figure 2).  
The MAVR microarray was composed of genotype-specific oligonucleotide probes 
selected to identify Sabin strains of OPV (GenBank accession nos. AY184219–AY184221); 
the selected sequences were spaced ~150 bases from each other in the viral genome, they 
contain a moderate amount of GC (Tm between 41 and 57°C), spots were printed in three 
rows according to their location in the genome. Each slide accommodates 5 individual 
microarrays for MAVR microarrays. Microarrays of immobilized oligonucleotide probes 
were hybridized with fluorescently-labeled viral cDNA prepared with hexanucleotide 
random primers and Superscript III reverse transcriptase. Each viral cDNA product (10 
µg) was fluorescently labeled with a Cy3 RNA Labeling Kit and purified using spin 
columns. Hybridization between microarray oligonucleotide probes and fluorescently-
labeled cDNA was performed as follow: vacuum-dried fluorescently-labeled cDNA 
samples were reconstituted in Hybridization Buffer and denatured by incubation for one 
minute at 95°C. A 10-µl aliquot of the hybridization mixture was applied to the 
microarray area and covered with an individual plastic cover slip. Hybridization was 
proceeded in an incubation chamber for two hours at 45°C. Fluorescent images of 
processed microarray slides were captured using ScanArray 5000. Any recombination in 
the analyzed viruses was detected as a change of fluorescent patterns of spots in the rows 
(clinical sample, Figure 2). 
One potential caveat regarding MAVR analysis is that it can positively identify 
recombinations only in regions derived from strains represented on the microarray. If one 
recombination partner is unknown, the microarray reveals a “gap” or an irregular pattern, 
calling for nucleotide sequencing as a tool of last resort. Alternatively, conserved 
oligonucleotide probes with broader specificity might be included in MAVR microarrays to 
tentatively identify the origin of “orphan” genomic segments. 
MAVR mapping of poliovirus genomes has an advantage over the more detailed complete 
nucleotide sequencing because it can determine more than one recombinant in the same 
samples without a need for cloning and has an extraordinary throughput. Restriction 
fragment length polymorphism (RFLP), also used for this purpose, is more time-
consuming and less informative than MAVR. In addition, MAVR analysis allows the 
genotyping of naturally heterogeneous populations. For example, the MARV analysis of a 
clinical sample (coded 18058) (Laassri et al., 2005) revealed a mixture of poliovirus strains 
composed of at least two and probably several more different types of recombinants. 
MAVR combined with cDNA preparation, coping of viral genome directly from clinical 
specimens (Laassri et al., 2005), opened the possibility of studying natural heterogeneity 
of viral populations in vivo. 
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Fig. 2. MAVR analysis of the genome structure of poliovirus. Three rows (coded 1, 2, and 3 
in the left of microarrays) of oligonucleotide probes in each microarray are specific to 3 
serotypes of poliovirus were spotted according to their location in the genome. Sample 
names are shown on the right. (a); Hybridization pattern of Sabin 1 genome with the MAVR 
microarray, (b); Represent the hybridization pattern of Sabin 2 genome with the MAVR 
microarray, (c); Hybridization pattern of Sabin 3 genome with the MAVR microarray, (c); 
Hybridization pattern of poliovirus genome extracted from a clinical sample obtained from 
acute flaccid paralysis (AFP).  
5. Microarray assay for quantitation of known virulent mutations 
Microarray assay for quantitation of known virulent mutations (MQNVM) was developed 
to quantify the virulent mutations in the genomes of the three serotypes of oral poliovirus 
vaccine (OPV) isolated from clinical specimens (Laassri et al., 2005; Laassri et al., 2006).  
Sabin strains of OPV mutate rapidly in vitro and in vivo. Some of these mutations are 
direct reversions to the alleles of wild-type progenitors of the vaccine strains, whereas 
others are second-site suppressors of the attenuated phenotype or are incidental changes. 
Among the best characterized attenuating mutations in the OPV Sabin strains are 
mutations located in the Internal Ribosome Entry Site (IRES) of the 5’-untranslated region 
(5’-UTR) (Minor, 1992) (Figure 3). These mutations have been identified in Sabin type 3 
poliovirus (472U→C) (Cann et al., 1984), as well as type 2 (481A→G) (Macadam et al., 
1993), and type 1 (480G→A and 525U→C) (Otelea et al., 1993); they are believed to 
selectively affect initiation of translation of viral polyprotein in neuronal cells (Guest et 
al., 2004; Svitkin et al., 1990). Previously was shown that the content of these revertants 
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was low in vaccine batches that failed the monkey neurovirulence test (Chumakov et al., 
1991). Sensitive mutant analysis by PCR and restriction enzyme cleavage (MAPREC) 
method is used to monitor the quantity of neurovirulent revertants in batches of oral 
poliovirus vaccine (Chumakov et al., 1991). However, the method is relatively labor-
intensive, and is not amenable to analysis of a large number of clinical samples that is 
needed for studies of genetic stability of vaccine viruses in vivo. Therefore, the 
development of high throughput methods to quantitate revertants in attenuated 
poliovirus remains a high priority for evaluation of existing and new vacines. 
Recently, an MQNVM assay (Figure 4A) was created to identify and quantitate the 4 
known reversions in the 5’-UTR of the 3 poliovirus strains (mutations located at 
nucleotides 480 and 525 for Sabin type 1, nucleotide 481 for Sabin type 2, and nucleotide 
472 for Sabin type 3); the assay has been described in detail elsewhere (Laassri et al., 2005; 
Laassri et al., 2006). 
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Fig. 3. Locations of the most important primary attenuating mutations of Sabin poliovirus in 
the IRES region of 5’-UTR of the genome. There are two known attenuating mutations for 
Sabin 1 (at nucleotides 480 and 525), one for Sabin 2 (at nucleotide 481) and one for Sabin 3 
(at nucleotide 525). 
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To prepare viral genomes directly from stool samples and to quantitate the reversions by 
MQNVM, 1 g of frozen stool was suspended in 10 ml of Dulbecco’s PBS, vortexed, 
centrifuged, and supernatants aliquoted and stored at -70ºC. Viral RNA was isolated from a 
total of 140 µl of stool supernatant. The extracted RNA was eluted in a final volume of 60 µl 
of sterile RNase-free water.  
For viral cDNA preparation, 10 µl of RNA was added to a reaction mixture containing 1 mM 
dithiothreitol, 2.5 µg/ml concentrations of each primer (A7-sabin1, 3 and A7-sabin2 (Laassri 
et al., 2005)), 0.5 mM dNTP mix, and 1x first-strand RT buffer. The final volume of the 
reaction mix is 50 µl. The mixture was heated for 5 min at 65ºC and then quickly chilled on 
ice. Superscript II reverse transcriptase (12 U/µl) was added to the mixture and incubated 
for two hours at 42ºC, then additional Superscript II reverse transcriptase (4 U/µl) was 
added, and the mixture incubated for another 3 hours at 42ºC. 
Full-length poliovirus genome from stool specimens was amplified by PCR (Laassri et al., 
2005). The reaction was performed with an XL-PCR kit. The viral full-length amplicons 
obtained from this PCR amplification were used for MQNVM analysis.  
The MQNVM microarrays (Figure 4A) contain 10 spots of oligonucleotide probe for a 
specific Sabin strain and 10 spots of oligonucleotide probe specific to the revertant virus. 
They also contain two oligonucleotides specific to a conserved region as control. Each 
control oligonucleotide was spotted 5 times in the last row. The redundant spotting of 
oligonucleotide probes was used to improve the quantitation accuracy. Ten individual 
MQNVM microarrays were spotted on each slide. Hybridization probes are single-stranded 
DNA (ssDNA) prepared by asymmetric PCR (Laassri et al., 2005). The ssDNA was purified 
with a PCR purification kit, and diluted in 50 µl of water. Aliquots containing 0.2 µM were 
labeled with a Cy5 or Cy3 RNA Labeling Kit and purified using spin columns. 
Several microarrays spotted on the same slide were simultaneously hybridized for 30 min at 
45ºC with fluorescently-labeled ssDNA samples prepared from the reference Sabin strain, 
reference Sabin revertant (or wild-type poliovirus), and one or more test strains. The 
microarray was then washed for 2 min in 2x standard saline citrate (SSC) with 0.1% sodium 
dodecyl sulfate (SDS), followed by one min in 2x SSC. 
Microarray images were taken with confocal fluorescent scanner ScanArray 5000 equipped 
with green and red HeNe lasers (543 nm and 632 nm that excite Cy3 and Cy5, respectively). 
Images were then analyzed using QuantArray software. The values obtained from MQNVM 
microarrays were normalized, and the percentage of reversion was calculated by dividing 
the normalized signal from each revertant oligonucleotide probe by the total signal (signal 
obtained from both revertant and vaccine oligonucleotide probes). The values obtained from 
10 replicates of each oligonucleotide probe (vaccine, revertant) were averaged, and the 
standard deviation calculated. 
To study the linearity of MQNVM assay to quantify mutants, another candidate vaccine virus 
such as West Nile (WN)/Dengue 4 chimeric virus, was used. An MQNVM microarray was 
developed as described above to analyze the mutation 2337G→C in West Nile/Dengue 4 virus 
(Laassri et al., 2011), and samples to contain different percentages of the mutant were spiked 
and analyzed by MQNVM assay, the detected percentages of mutants were plotted against the 
expected percentages of mutants (Figure 4B). Results demonstrate that mutant quantitation by 
MQNVM assay is linear, indicating that this assay is suitable to quantitate mutants. 
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Fig. 4. Layout of a microarray for quantitation of known virulent mutations (MQNVM) in 
Sabin strains, the hybridization pattern of Sabin strains and their revertants, and the 
linearity of mutants quantitation with MQNVM assay. 
(A): 1) Detection of the 480G→A and 525U→C revertants in the Sabin strain type-1 of 
poliovirus. The first microarray shows the layout of oligonucleotide probes: 10 spots each of 
4 allele-specific oligonucleotide probes were spotted into the top 4 rows; the bottom row 
contains 5 spots each of a universal oligonucleotide probe and of a Sabin1-specific 
oligonucleotide probe. The second, third and fourth microarrays show patterns of 
hybridization of, respectively, Sabin 1, Mahoney (wild-type poliovirus type 1), and revertant 
strain 11262 (poliovirus type 1). 2) Detection of 481A→G revertants in Sabin 2 strain. The 
first microarray shows the layout of oligonucleotide probes: 10 spots each of two allele-
specific oligonucleotide probes were spotted onto the top 2 rows; the bottom row contains 5 
spots each of universal oligonucleotide probe and Sabin 2-specific oligonucleotide probe. 
The second and third microarrays show patterns of hybridization of, respectively, Sabin 2 
strain, and revertant strain 154 (poliovirus type 2). 3) Detection of the 472U→C revertants in 
Sabin 3 strain. The first microarray shows the layout of oligonucleotide probes: 10 spots each 
of two allele-specific oligonucleotide probes were spotted into the top two rows; the bottom 
row contains 5 spots each of universal oligonucleotide probe and Sabin3-specific 
oligonucleotide probe. The second and third microarrays show patterns of hybridization of, 
respectively, Sabin 3 strain, and Leon/37 (wild type poliovirus type 3). (B): Evaluation of the 
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linearity of a quantitative MQNVM assay. Samples containing different amounts of 
WN/Dengue 4 virus 2337G→C mutant were analyzed by MQNVM assay. The results were 
plotted as observed versus the expected mutant contents. This result shows that mutants 
quantitation with MQNVM assay is linear with R-squared value (R2) equal 0.99. 
Also, MQNVM assay was used to characterize poliovirus in about 300 stool specimens 
obtained from children vaccinated with different combinations of OPV and inactivated polio 
vaccine (IPV) (Laassri et al., 2005; Laassri et al., 2006). The PCR-amplified viral cDNA 
prepared directly from the stool specimens was used to quantitate reversions in the 5’-UTR 
of each of the 3 poliovirus serotypes. Fluorescently-labeled ssDNA for hybridization was 
prepared form each poliovirus serotype as described above and elsewhere (Laassri et al., 
2005). Results of our study (Laassri et al., 2006) show that many stool samples from healthy 
children one week after OPV vaccination contained different percentages of revertants, 
consistent with earlier observations based on conventional methodology (Cann et al., 1984; 
Kew et al., 2002; WHO, 2002). The oligonucleotide microarrays simultaneously detected and 
discriminated between vaccine and revertant sequences and allowed the quantitation of 
reversions in the 5’-UTRs of all 3 serotypes of poliovirus. 
6. Conclusion 
Microarray technology is a sensitive and versatile method for genetic analysis that allows 
screening of mutations in genetic materials and readily detecting single-point mutations. 
Viral nucleic acid hybridization with immobilized oligonucleotides in microarrays that 
encompass thousands of individual probes offers a rapid method suitable for simultaneous 
analysis of a large number of markers distributed over the whole viral genome. The 
technique generates instant genetic maps of mutant strains and reveals evolutionary 
divergence and mutational profiles of individual viral stocks. 
The simplicity and high throughput of microarray-based analyses might also assist in 
improving genetic stability of candidate vaccine strains by incorporating mutations 
conferring better replicative properties. They also facilitate monitoring of molecular 
consistency in a new viral vaccine during its manufacturing. The same approach can be 
applied in future development of new live viral vaccines and used as a new paradigm for 
better quality control tests of vaccines against other pathogens.  
The oligonucleotide microarrays described in this chapter have already facilitated the 
analysis of the genetic diversity of viruses and live virus vaccines at the levels of genomic 
recombination, nucleotide sequence heterogeneity, and quantitation of single-point 
mutations. They facilitate rapid analysis of viral genes and genomes, circumventing 
traditional methods that usually involve much more laborious efforts. Microarray methods 
can analyze a very large number of samples simultaneously, within few hours. Furthermore, 
cloning of nucleic acids is not required, thus preserving the natural genomic composition of 
viral gene populations. Microarray methods open the possibility of a large-scale full-genome 
screening of viral isolates needed for improved epidemiological surveillance and better 
vaccine quality control; for example, MQNVM microarrays rapidly, simultaneously, and 
unambiguously identified viral vaccines and their revertants and quantified the amounts of 
single-point mutations. 
Unlike direct DNA sequencing, the MARSH assay determines only the approximate location 
of mutations within a single oligonucleotide probe. However, this limitation has the 
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advantage of increasing the sensitivity of detecting genomic changes by microarray, since it 
reveals several adjacent mutations on different molecules, even mutations present in 
quantities too low to detect by conventional sequencing (Cherkasova et al., 2003). 
Besides having a high throughput capacity the MARV assay easily demonstrates naturally 
heterogeneous viral populations, even in the same sample, without the need to separate or 
clone them.  
Microarray-based assays for genetic stability of live viral vaccines should greatly assist in 
evaluating safety. The information obtained from such microarray methods will not only 
expedite regulatory review of the prospective recombinant vaccines but also provide a method 
suitable for monitoring consistency of vaccine production as part of routine quality control. 
Microarray techniques also offer the possibility for a large-scale full-genome screening of viral 
isolates to improve epidemiological surveillance, and better vaccine quality control. 
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